Dr. Rajan had disclosed that he is a consultant for Baxter International Inc., Alexion Pharmaceuticals, Biogen Idec, and Incyte Corporation; he receives honoraria from Alexion Pharmaceuticals; is on the speakers’ bureau for Alexion Pharmaceuticals and Biogen Idec; and receives research support from Incyte Corporation. Dr. Armitage has disclosed that he is a consultant for Celgene Corporation, GlaxoSmithKline, Roche, Spectrum Pharmaceuticals, Inc., and ZIOPHARM Oncology, Inc; and is on the Board of Directors for TESARO, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.
The authors would like to thank Christine Higgins and Pamela Althof for their help in conducting cytogenetic and fluorescence in situ hybridization studies.
Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:285–293.
Gangat N, Wolanskyj AP, McClure RF et al.. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007;21:270–276.
Wolanskyj AP, Schwager SM, McClure RF et al.. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159–166.
Chim CS, Kwong YL, Lie AK et al.. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005;165:2651–2658.
Muringampurath-John D, Jaye DL, Flowers CR et al.. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol 2012;158:608–614.
Frederiksen H, Farkas DK, Christiansen CF et al.. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011;118:6515–6520.
Vannucchi AM, Masala G, Antonioli E et al.. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009;18:2068–2073.
Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007;136:745–751.
Tefferi A, Vaidya R, Caramazza D et al.. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356–1363.
Palandri F, Catani L, Testoni N et al.. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol 2009;84:215–220.
Harrison C, Kiladjian JJ, Al-Ali HK et al.. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798.
Verstovsek S, Mesa RA, Gotlib J et al.. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365:1455–1457.
Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188–1191.
Verstovsek S, Kantarjian H, Mesa RA et al.. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New Engl J Med 2010;363:1117–1127.
Czene K, Adami HO, Chang ET. Sex- and kindred-specific familial risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:2496–2499.
Cuttner J, Wallenstein S, Troy K. Non-Hodgkin’s lymphoma in patients 70 years of age or older: factors associated with survival. Leuk Res 2002;26:447–450.
Palandri F, Derenzini E, Ottaviani E et al.. Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. Leuk Lymphoma 2009;50:481–484.